83 FR 13519 - Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals, Inc.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration Federal Register Volume 83, Issue 61 (March 29, 2018)
Drug Enforcement Administration
Federal Register Volume 83, Issue 61 (March 29, 2018)
| Page Range | 13519-13519 | |
| FR Document | 2018-06327 |
[Federal Register Volume 83, Number 61 (Thursday, March 29, 2018)] [Notices] [Page 13519] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-06327] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-392] Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals, Inc. ACTION: Notice; Correction. ----------------------------------------------------------------------- SUMMARY: The Drug Enforcement Administration (DEA) published a document in the Federal Register on February 6, 2018, concerning a notice of application that inadvertently did not include the controlled substance levorphanol (9220). Correction In the Federal Register on February 6, 2018, in FR Doc No: 2018- 02343 (83 FR 5274), correct the table to include the following basic class of controlled substance: ------------------------------------------------------------------------ Controlled substance Drug code Schedule ------------------------------------------------------------------------ Levorphanol.......................... 9220 II ------------------------------------------------------------------------ Dated: March 15, 2018. Susan A. Gibson, Deputy Assistant Administrator. [FR Doc. 2018-06327 Filed 3-28-18; 8:45 am] BILLING CODE 4410-09-P
![Federal Register / Vol. 83, No. 61 / Thursday, March 29, 2018 / Notices 13519
patent the Commission determined to imported by or on behalf of document in the Federal Register on
review (1) the ID’s finding that a Respondents or any of their affiliated February 6, 2018, concerning a notice of
combination of prior art references companies, parents, subsidiaries, agents, application that inadvertently did not
Doppelt, Jacobs, and Gilbert fail to or other related business entities, or include the controlled substance
render the asserted claims obvious; and their successors or assigns, are excluded levorphanol (9220).
(2) the ID’s finding that a combination from entry for consumption into the Correction
of prior art references Matsuoka, United States, entry for consumption
Doppelt, and Eckel fail to render the from a foreign-trade zone, or withdrawal In the Federal Register on February 6,
asserted claims obvious. For the ’336 from a warehouse for consumption, for 2018, in FR Doc No: 2018–02343 (83 FR
patent the Commission determined to the remaining term of the ’319 patent 5274), correct the table to include the
review (1) the ID’s finding that claim 34 except under license of the patent following basic class of controlled
recites ineligible patent subject matter owner or as provided by law; and (2) substance:
under 35 U.S.C. 101; and (2) the ID’s cease and desist orders prohibiting TTi
finding that Pruessel, either alone or in Controlled
HK, TTi NA, One World, and OWT from substance Drug code Schedule
combination with Koestler, fails to conducting any of the following
render claim 34 obvious. The activities in the United States: Levorphanol ............ 9220 II
Commission requested the parties to Importing, selling, marketing,
brief certain issues. Id. On January 5, advertising, distributing, transferring Dated: March 15, 2018.
2018, the parties filed submissions to (except for exportation), and soliciting
the Commission’s question and on Susan A. Gibson,
U.S. agents or distributors for, access
remedy, the public interest, and Deputy Assistant Administrator.
control systems and components thereof
bonding. See Complainant’s Response to [FR Doc. 2018–06327 Filed 3–28–18; 8:45 am]
covered by one or more of claims 1–4,
Request for Written Submissions 7–12, 15, and 16 of the ’319 patent. BILLING CODE 4410–09–P
Regarding Issues Under Review; The Commission has also determined
Respondents’ Response to Request for that the public interest factors
Written Submissions Regarding Issues enumerated in section 337(d) and (f) (19 DEPARTMENT OF JUSTICE
Under Review. On January 12, 2018, the U.S.C. 1337(d) and (f)) do not preclude Drug Enforcement Administration
parties filed reply submissions. See issuance of the limited exclusion order
Complainant’s Reply to Respondents’ or cease and desist orders. Finally, the [Docket No. DEA–392]
Submission Addressing the Commission has determined that a bond
Commission’s December 22, 2017 in the amount of zero is required to Importer of Controlled Substances
Notice; Respondents’ Reply to permit temporary importation during Application: Fisher Clinical Services,
Complainant’s Submission Regarding Inc.
the period of Presidential review (19
Issues Under Review. U.S.C. 1337(j)) of access control system
Having examined the record of this ACTION: Notice of application.
and components thereof that are subject
investigation, including the final ID, and to the remedial orders. The DATES: Registered bulk manufacturers of
the parties’ submissions, for the ’319 Commission’s orders and opinion were the affected basic classes and applicants
patent the Commission has determined delivered to the President and to the therefore, may file written comments on
to (1) affirm the ALJ’s finding that a United States Trade Representative on or objections to the issuance of the
combination of prior art references the day of their issuance. proposed registration on or before April
Doppelt, Jacobs, and Gilbert fail to The authority for the Commission’s 30, 2018. Such persons may also file a
render the asserted claims obvious and determination is contained in section written request for a hearing on the
(2) affirm the ALJ’s finding that a 337 of the Tariff Act of 1930, as application on or before April 30, 2018.
combination of prior art references amended (19 U.S.C. 1337), and in Part
Matsuoka, Doppelt, and Eckel fail to ADDRESSES: Written comments should
210 of the Commission’s Rules of be sent to: Drug Enforcement
render the asserted claims obvious, but Practice and Procedure (19 CFR part
reverse the ALJ’s finding that Eckel is Administration, Attention: DEA Federal
210). Register Representative/DRW, 8701
analogous art. For the ’336 patent the
Commission has determined to (1) By order of the Commission. Morrissette Drive, Springfield, Virginia
affirm the ALJ’s finding that Pruessel, Issued: March 23, 2018. 22152. All requests for hearing must be
either alone or in combination with Katherine Hiner, sent to: Drug Enforcement
Koestler, fails to render claim 34 Supervisory Attorney. Administration, Attn: Administrator,
obvious and (2) take no position on the [FR Doc. 2018–06293 Filed 3–28–18; 8:45 am]
8701 Morrissette Drive, Springfield,
ALJ’s finding that claim 34 recites Virginia 22152. All requests for hearing
BILLING CODE 7020–02–P
ineligible patent subject matter under 35 should also be sent to: (1) Drug
U.S.C. 101. The Commission adopts the Enforcement Administration, Attn:
ID’s findings to the extent they are not Hearing Clerk/LJ, 8701 Morrissette
DEPARTMENT OF JUSTICE Drive, Springfield, Virginia 22152; and
inconsistent with the Commission
opinion issued herewith. Drug Enforcement Administration (2) Drug Enforcement Administration,
Having found a violation of section Attn: DEA Federal Register
337 in this investigation, the [Docket No. DEA–392] Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
sradovich on DSK3GMQ082PROD with NOTICES
Commission has determined that the
appropriate form of relief is: (1) A Bulk Manufacturer of Controlled
SUPPLEMENTARY INFORMATION:
limited exclusion order prohibiting the Substances Application: Chattem The Attorney General has delegated
unlicensed entry of access control Chemicals, Inc. his authority under the Controlled
systems and components thereof that ACTION: Notice; Correction. Substances Act to the Administrator of
infringe one or more of claims 1–4, 7– the Drug Enforcement Administration
12, 15, and 16 of the ’319 patent that are SUMMARY: The Drug Enforcement (DEA), 28 CFR 0.100(b). Authority to
manufactured by, or on behalf of, or are Administration (DEA) published a exercise all necessary functions with
VerDate Sep<11>2014 19:09 Mar 28, 2018 Jkt 244001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\29MRN1.SGM 29MRN1](https://thefederalregister.org/doc/83_FR_13580/page/1.svg)
Document Created: 2018-03-29 00:25:21
Document Modified: 2018-03-29 00:25:21
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice; Correction. | |
| FR Citation | 83 FR 13519 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR